Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group Study 9916

Seminars in Oncology

Volumn 26, Issue 5 SUPPL. 17, 1999, Pages 55-60

  Hussain, M ^a   Petrylak, D ^a   Fisher, E ^a   Tangen, C ^a   Crawford, D ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; HYDROCORTISONE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THROMBOCYTOPENIA;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; ESTRAMUSTINE; HUMANS; MALE; MITOXANTRONE; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PREDNISONE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0033432697     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)